We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...
Figure 1: A new W-shaped structural model of E22G 40-residue beta-amyloid fibrils. RIKEN researchers have shown how the ...
Buntanetap is an innovative drug designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This ...
Prothena is evaluating PRX012 — a wholly owned investigational next-generation subcutaneous, single-injection once-monthly antibody delivered subcutaneously targeting a key epitope at the N-terminus ...
In recent years, the focus of clinical development has been on immunotherapeutic compounds aimed at clearing brain ...
The company’s lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers. Read More on ABOS: Acumen Pharmaceuticals NewsMORE Related Stocks Indices ...
AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...
Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble ...
Dr Charles Vega believes that primary care will be the chief clinical setting for application of new blood-based biomarkers.
New research offers hope for delaying Alzheimer’s disease progression by years after initial diagnosis. Alzheimer’s disease is a leading cause of death among those aged 65 or older. As the most common ...